MedPharm Expands Testing Models to Target Coronavirus
By Contact Pharma Staff | 04.28.20
Helps accelerate treatment development prior to clinical trials
These models are based on air liquid interface tissue culture of primary human cells from different regions of the respiratory system which are then infected with relevant corona viral strains.
“Finding effective new treatments quickly for these viral infections is imperative in these extraordinary times,” said Jon Lenn, chief technology officer, MedPharm.
Jon Volmer, MedPharm’s senior director of research biology and innovation, said, “We are looking forward to applying such a useful high throughput model to the development of new therapies for current and future coronaviruses.”